Compare Eli Lilly And Co (LLY) vs Motorola Solutions Inc (MSI) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

MSI trades at $412.34, down 0.23% on the day, with a neutral technical signal. The company shows strong profitability with a 17.61% net income margin and has beaten earnings estimates for three consecutive quarters. Recent developments include the $1.5 billion acquisition of D-Fend Solutions and expansion of AI capabilities for emergency response systems, indicating strategic growth in public safety technology.

The outlook remains positive with a consensus price target of $512.33, representing 24% upside potential. Key risks include high valuation multiples and significant investing cash outflows from acquisitions. Analyst sentiment is bullish with 70.59% buy ratings, though investors should monitor integration execution of recent deals and competitive pressures in the tech sector.